Skip to main content

Animations

MJFF Publications

2751 - 2760 of 8808 Results
Title
Year
  • Year
  • 2024
  • 2025
  • 2005
  • 2013
  • 2022
  • 2022
  • 2016
  • 2025
  • 2021
  • 2025
  • Summary Details
    OPEN
    Title: Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions
    Journal Name: Neuron
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuron.2024.06.002
    Citation Count: 12
  • Summary Details
    OPEN
    Title: A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd, cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1038/s41591-025-03565-2
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity
    Journal Name: BMC Neuroscience
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1186/1471-2202-6-71
    Citation Count: 66
  • Summary Details
    OPEN
    Title: A Neo-Substrate that Amplifies Catalytic Activity of Parkinson’s-Disease-Related Kinase PINK1
    Journal Name: Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.cell.2013.07.030
    Citation Count: 252
  • Summary Details
    OPEN
    Title: Brain-restricted mTOR inhibition with binary pharmacology
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41586-022-05213-y
    Citation Count: 60
  • Summary Details
    OPEN
    Title: Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/mds.29184
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1073/pnas.1610099113
    Citation Count: 238
  • Summary Details
    RESTRICTED
    Title: Shared and disease-specific pathways in frontotemporal dementia and Alzheimer’s and Parkinson’s diseases
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41591-025-03833-1
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Remote smartphone monitoring of Parkinson’s disease and individual response to therapy
    Journal Name: Nature Biotechnology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41587-021-00974-9
    Citation Count: 117
  • Summary Details
    OPEN
    Title: EndoMAP.v1 charts the structural landscape of human early endosome complexes
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41586-025-09059-y
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.